• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.胸腔中性粒细胞与淋巴细胞比值与 IV 期非小细胞肺癌的早期疾病进展相关。
In Vivo. 2020 Jul-Aug;34(4):2179-2185. doi: 10.21873/invivo.12027.
2
The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.外周血中性粒细胞与淋巴细胞比值是接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗的表皮生长因子受体(EGFR)突变的非小细胞肺癌患者生存情况的预后预测指标。
Medicine (Baltimore). 2018 Jul;97(30):e11648. doi: 10.1097/MD.0000000000011648.
3
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.中性粒细胞与淋巴细胞比值作为接受酪氨酸激酶抑制剂治疗的欧洲表皮生长因子受体突变型非小细胞肺癌患者的预后因素。
Oncol Res Treat. 2018;41(12):755-761. doi: 10.1159/000492344. Epub 2018 Nov 13.
4
The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.预后营养指数(PNI)和中性粒细胞与淋巴细胞比值(NLR)对铂类化疗治疗晚期非小细胞肺癌的预后价值。
Ann Palliat Med. 2020 May;9(3):967-978. doi: 10.21037/apm.2020.04.31. Epub 2020 Apr 21.
5
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?治疗前中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值对预测小细胞肺癌患者的预后是否有用?
Oncotarget. 2017 Jun 6;8(23):37200-37207. doi: 10.18632/oncotarget.16553.
6
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.系统免疫炎症指数、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值可预测纳武利尤单抗治疗转移性非小细胞肺癌患者的临床结局。
J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8.
7
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.EGFR 突变型 NSCLC 患者接受酪氨酸激酶抑制剂治疗时中性粒细胞与淋巴细胞比值的影响。
Invest New Drugs. 2020 Jun;38(3):885-893. doi: 10.1007/s10637-020-00919-0. Epub 2020 Mar 10.
8
[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].[治疗前中性粒细胞与淋巴细胞比值(NLR)对接受胸部放疗的局部晚期非小细胞肺癌患者的预后价值]
Zhonghua Zhong Liu Za Zhi. 2018 Jun 23;40(6):446-451. doi: 10.3760/cma.j.issn.0253-3766.2018.06.009.
9
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.中性粒细胞与淋巴细胞比值(NLR)作为 IV 期非小细胞肺癌不良预后的指标。
Clin Transl Oncol. 2012 Nov;14(11):864-9. doi: 10.1007/s12094-012-0872-5. Epub 2012 Jul 19.
10
Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.升高的预处理血小板与淋巴细胞比值与伴恶性胸腔积液的 IV 期非小细胞肺癌患者的不良生存相关。
Sci Rep. 2019 Mar 18;9(1):4721. doi: 10.1038/s41598-019-41289-9.

引用本文的文献

1
Development a predictive nomogram for spontaneous pleurodesis in patients with non-small cell lung cancer and malignant pleural effusion.开发一种用于预测非小细胞肺癌合并恶性胸腔积液患者自发性胸膜固定术的列线图。
J Thorac Dis. 2025 Feb 28;17(2):1013-1027. doi: 10.21037/jtd-2025-31. Epub 2025 Feb 27.
2
Predictive Value of Neutrophil-to-Lymphocyte Ratio for Immune Checkpoint Inhibitor-Related Myocarditis Among Patients Treated for Non-Small-Cell Lung Cancer.非小细胞肺癌患者中中性粒细胞与淋巴细胞比值对免疫检查点抑制剂相关心肌炎的预测价值
Cancer Innov. 2025 Feb 20;4(2):e163. doi: 10.1002/cai2.163. eCollection 2025 Apr.
3
Comparison of five scores to predict mortality in malignant pleural effusion.五种预测恶性胸腔积液死亡率评分的比较。
Updates Surg. 2024 Dec;76(8):2885-2892. doi: 10.1007/s13304-024-01985-2. Epub 2024 Sep 23.
4
Elevation of Neutrophil-to-Lymphocyte Ratio Is a Significant Poor Prognostic Factor in Completely Resected Centrally Located Lung Squamous Cell Carcinoma.中性粒细胞与淋巴细胞比值升高是完全切除的中央型肺鳞癌的一个显著不良预后因素。
In Vivo. 2022 Sep-Oct;36(5):2303-2307. doi: 10.21873/invivo.12960.
5
A Preliminary Study on the Prognostic Impact of Neutrophil to Lymphocyte Ratio of the Bronchoalveolar Lavage Fluid in Patients with Lung Cancer.肺癌患者支气管肺泡灌洗液中性粒细胞与淋巴细胞比值对预后影响的初步研究
Diagnostics (Basel). 2021 Nov 25;11(12):2201. doi: 10.3390/diagnostics11122201.
6
Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗的晚期非小细胞肺癌患者中,衍生中性粒细胞与淋巴细胞比率及中性粒细胞与淋巴细胞比率早期变化的可预测性
J Thorac Dis. 2021 May;13(5):2824-2832. doi: 10.21037/jtd-20-3416.
7
Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.恶性胸腔积液中性粒细胞与淋巴细胞比值:预后意义。
PLoS One. 2021 Apr 26;16(4):e0250628. doi: 10.1371/journal.pone.0250628. eCollection 2021.

本文引用的文献

1
Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.血小板计数与淋巴细胞/单核细胞比值联合对伴有恶性胸腔积液的 IV 期非小细胞肺癌的预后价值。
PLoS One. 2018 Jul 13;13(7):e0200341. doi: 10.1371/journal.pone.0200341. eCollection 2018.
2
Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.一种利用血清中性粒细胞与淋巴细胞比值和恶性胸腔积液对肺癌患者进行预后评估的新评分方法的预后影响。
BMC Cancer. 2017 Aug 22;17(1):557. doi: 10.1186/s12885-017-3550-8.
3
Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study.术前血小板计数与中性粒细胞-淋巴细胞比值联合(COP-NLR)在非小细胞肺癌患者中的预后意义:基于一项大型队列研究
PLoS One. 2015 May 7;10(5):e0126496. doi: 10.1371/journal.pone.0126496. eCollection 2015.
4
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.利用肺癌致癌驱动基因的多重分析来选择靶向药物。
JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.
5
Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion.Th1 和 Th17 细胞在恶性胸腔积液小鼠模型中的相互作用。
Am J Respir Crit Care Med. 2014 Mar 15;189(6):697-706. doi: 10.1164/rccm.201310-1776OC.
6
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.基线和最低点中性粒细胞指数对非小细胞肺癌和卵巢癌患者的影响:评估化疗对不良中性粒细胞增多症的缓解情况。
J Transl Med. 2013 Aug 15;11:189. doi: 10.1186/1479-5876-11-189.
7
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.血管内皮生长因子在恶性胸腔积液发病机制、诊断和治疗中的作用。
Curr Oncol Rep. 2013 Jun;15(3):207-16. doi: 10.1007/s11912-013-0315-7.
8
Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.贝伐珠单抗联合顺铂治疗非小细胞肺癌所致恶性胸腔积液。
Oncol Rep. 2013 Jun;29(6):2332-40. doi: 10.3892/or.2013.2349. Epub 2013 Mar 15.
9
Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.治疗前中性粒细胞与淋巴细胞比值与一线含铂化疗治疗的晚期非小细胞肺癌患者的治疗反应和预后相关。
Cancer Immunol Immunother. 2013 Mar;62(3):471-9. doi: 10.1007/s00262-012-1347-9. Epub 2012 Sep 18.
10
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.中性粒细胞与淋巴细胞比值(NLR)作为 IV 期非小细胞肺癌不良预后的指标。
Clin Transl Oncol. 2012 Nov;14(11):864-9. doi: 10.1007/s12094-012-0872-5. Epub 2012 Jul 19.

胸腔中性粒细胞与淋巴细胞比值与 IV 期非小细胞肺癌的早期疾病进展相关。

Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.

机构信息

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

出版信息

In Vivo. 2020 Jul-Aug;34(4):2179-2185. doi: 10.21873/invivo.12027.

DOI:10.21873/invivo.12027
PMID:32606202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7439889/
Abstract

BACKGROUND/AIM: While blood neutrophil-to-lymphocyte ratio (NLR) has been associated with poor prognosis in NSCLC, however few studies have focused on pleural fluid white blood cell differential count. We conducted a retrospective multicenter cohort study to evaluate the predictive value of pleural NLR in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE).

PATIENTS AND METHODS

From the multicenter lung cancer cohort, 134 epidermal growth factor receptor (EGFR) wild-type patients with NSCLC were selected for evaluation. Receiver operating characteristic (ROC) curve analysis was performed for pretreatment pleural NLR to determine the cut-off value for predicting disease progression within 100 days after the diagnosis.

RESULTS

The low-pleural NLR group showed significantly longer overall survival (OS) and progression free survival (PFS) compared to the high-pleural NLR group. After stratification using quartile cut-off values of pleural NLR, the correlation between risk of disease progression and pleural NLR was shown to be dose-dependent. The multivariate analysis on PFS showed that high-pleural NLR (p=0.004) was an independent predictor for shorter PFS with HR of 1.036 (1.011-1.061).

CONCLUSION

Increased pleural NLR is predictive of early disease progression in EGFR mutation wild-type NSCLC patients with MPE.

摘要

背景/目的:虽然血液中性粒细胞与淋巴细胞比值(NLR)与非小细胞肺癌(NSCLC)的预后不良相关,但很少有研究关注胸腔液白细胞分类计数。我们进行了一项回顾性多中心队列研究,以评估胸膜 NLR 在非小细胞肺癌(NSCLC)合并恶性胸腔积液(MPE)患者中的预测价值。

患者和方法

从多中心肺癌队列中,选择了 134 例表皮生长因子受体(EGFR)野生型 NSCLC 患者进行评估。对预处理胸膜 NLR 进行接受者操作特征(ROC)曲线分析,以确定预测诊断后 100 天内疾病进展的截断值。

结果

低胸膜 NLR 组的总生存期(OS)和无进展生存期(PFS)明显长于高胸膜 NLR 组。根据胸膜 NLR 的四分位截断值进行分层后,疾病进展风险与胸膜 NLR 之间的相关性呈剂量依赖性。PFS 的多变量分析显示,高胸膜 NLR(p=0.004)是 MPE 中 EGFR 突变野生型 NSCLC 患者较短 PFS 的独立预测因子,HR 为 1.036(1.011-1.061)。

结论

胸膜 NLR 升高可预测 EGFR 突变野生型 NSCLC 合并 MPE 患者的早期疾病进展。